Although the sample size is limited, these clinical sample results further corroborate our findings on STAT3-mediated SUSD2 upregulation in EGFR+ HER2+ breast cancer, underscoring the clinical significance of SUSD2 expression. This evidence concerns the gene STAT3 and breast cancer.